moxifloxacin has been researched along with fentanyl in 6 studies
Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (fentanyl) | Trials (fentanyl) | Recent Studies (post-2010) (fentanyl) |
---|---|---|---|---|---|
3,157 | 552 | 1,690 | 15,288 | 4,310 | 4,483 |
Protein | Taxonomy | moxifloxacin (IC50) | fentanyl (IC50) |
---|---|---|---|
ATP-dependent translocase ABCB1 | Homo sapiens (human) | 6.5 | |
Delta-type opioid receptor | Mus musculus (house mouse) | 0.6342 | |
Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0122 | |
Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.1888 | |
Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0122 | |
Mu-type opioid receptor | Homo sapiens (human) | 0.0058 | |
Delta-type opioid receptor | Homo sapiens (human) | 0.3092 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 5.893 | |
Kappa-type opioid receptor | Homo sapiens (human) | 1.58 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0031 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.8197 | |
Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 4.973 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.354 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Nagashima, R; Nishikawa, T; Tobita, M | 1 |
Jolivette, LJ; Ward, KW | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
6 other study(ies) available for moxifloxacin and fentanyl
Article | Year |
---|---|
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |